

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) A method for treating a skin disorder comprising introducing a polynucleotide subcutaneously using a needleless syringe.
2. (Currently Amended) A method for treating a skin disorder comprising ~~injecting/subcutaneously~~ injecting or subcutaneously introducing a polynucleotide around diseased skin using a needleless syringe.
3. (Original) The method of claim 1 or 2, wherein the polynucleotide is selected from a DNA, oligonucleotide, RNA, siRNA, and antisense.
4. (Currently Amended) The method of ~~any one of claims 1 to 3~~ claim 3, comprising ~~injecting/subcutaneously~~ injecting or subcutaneously introducing 10 µg to 10 mg of the polynucleotide per dose in portions to multiple sites around the diseased skin.
5. (Currently Amended) The method of ~~any one of claims 1 to 4~~ claim 1 or 2, wherein the needleless syringe injects a pharmaceutical liquid by using a gas pressure or an elastic force of an elastic member to drive a piston.
6. (Original) The method of claim 5, wherein the gas is helium, nitrogen, or air, and the elastic member is a spring.
7. (Currently Amended) The method of ~~any one of claims 1 to 6~~ claim 1 or 2, wherein the polynucleotide is- comprises hepatocyte growth factor (HGF) gene and/or prostacyclin synthetase (PGIS) gene, prostacyclin synthetase (PGIS) gene, or both.

8. (Currently Amended) The method of ~~any one of claims 1 to 7~~ claim 3, wherein the oligonucleotide is an NF- κ B decoy oligonucleotide comprising the sequence of SEQ ID NO: 1 or 2.

9. (Currently Amended) The method of ~~any one of claims 1 to 8~~ claim 1 or 2, wherein the skin disorder is a wound, cutaneous ulcer, or psoriasis.

10. (Currently Amended) The method of ~~any one of claims 1 to 9~~ claim 9, wherein the wound is a post-surgical wound or a wound caused by an injury or accident.

11. (Currently Amended) The method of ~~any one of claims 1 to 10~~ claim 9, wherein the cutaneous ulcer is an intractable cutaneous ulcer.

12. (Currently Amended) The method of ~~any one of claims 1 to 11~~ claim 11, wherein the intractable cutaneous ulcer is a diabetic ulcer, bed sore (pressure ulcer), or ulcer associated with venous or arterial insufficiency.

13. (Currently Amended) A method for treating a wound or cutaneous ulcer, comprising ~~injecting/subcutaneously~~ injecting or subcutaneously introducing an HGF gene ~~and/or~~ or PGIS gene around diseased skin using a needleless syringe.

14. (Currently Amended) The method of claim 13, comprising ~~injecting/subcutaneously~~ injecting or subcutaneously introducing the HGF gene and PGIS gene around the diseased skin using a needleless syringe.

15. (Currently Amended) A method for treating psoriasis, comprising ~~injecting/subcutaneously~~ injecting or subcutaneously introducing an NF- κ B decoy oligonucleotide around diseased skin using a needleless syringe.

16. (Original) An agent for treating, ameliorating, or preventing a skin disorder, comprising a polynucleotide as an active ingredient, wherein the agent is introduced subcutaneously using a needleless syringe.

17. (Currently Amended) An agent for treating, ameliorating, or preventing a skin disorder, comprising a polynucleotide as an active ingredient, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced around diseased skin using a needleless syringe.

18. (Original) The agent of claim 16 or 17, wherein the polynucleotide is selected from a DNA, oligonucleotide, RNA, siRNA, and antisense.

19. (Currently Amended) The agent of ~~any one of claims 16 to 18~~ claim 18, comprising 10 µg to 10 mg of the polynucleotide per dose as an active ingredient, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced in portions to multiple sites around the diseased skin.

20. (Currently Amended) The agent of ~~any one of claims 16 to 19~~ claim 16 or 17, wherein the needleless syringe injects a pharmaceutical liquid by using a gas pressure or an elastic force of an elastic member to drive a piston.

21. (Original) The agent of claim 20, wherein the gas is helium, nitrogen, or air, and the elastic member is a spring.

22. (Currently Amended) The agent of ~~any one of claims 16 to 21~~ claim 16 or 17, wherein the polynucleotide is comprises an HGF gene ~~and/or PGIS gene~~ , a PGIS gene, or both.

23. (Currently Amended) The agent of ~~any one of claims 16 to 22~~ claim 18, wherein the oligonucleotide is an NF-κB decoy oligonucleotide comprising the sequence of SEQ ID NO: 1 or 2.

24. (Currently Amended) The agent of ~~any one of claims 16 to 23~~ claim 16 or 17, wherein the skin disorder is a wound, cutaneous ulcer, or psoriasis.

25. (Currently Amended) The agent of ~~any one of claims 16 to 24~~ claim 24, wherein the wound is a post-surgical wound or a wound caused by an injury or accident.

26. (Currently Amended) The agent of ~~any one of claims 16 to 25~~ claim 24, wherein the cutaneous ulcer is an intractable cutaneous ulcer.

27. (Currently Amended) The agent of ~~any one of claims 16 to 26~~ claim 26, wherein the intractable cutaneous ulcer is a diabetic ulcer, bedsore (pressure ulcer), or ulcer associated with venous or arterial insufficiency.

28. (Currently Amended) An agent for treating, ameliorating, or preventing a wound or cutaneous ulcer, comprising an HGF gene ~~and/or~~ or PGIS gene as an active ingredient, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced around diseased skin using a needleless syringe.

29. (Currently Amended) The agent of claim 28, comprising an HGF gene and a PGIS gene as active ingredients, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced around diseased skin using a needleless syringe.

30. (Currently Amended) An agent for treating, ameliorating, or preventing psoriasis, comprising an NF- κ B decoy oligonucleotide as an active ingredient, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced around diseased skin using a needleless syringe.

31. (Original) Use of a polynucleotide for preparing an agent for treating, ameliorating, or preventing a skin disorder, wherein the agent is introduced subcutaneously using a needleless syringe.

32. (Currently Amended) Use of a polynucleotide for preparing an agent for treating, ameliorating, or preventing a skin disease, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced around diseased skin using a needleless syringe.

33. (Original) The use of claim 31 or 32, wherein the polynucleotide is any one selected from a DNA, oligonucleotide, RNA, siRNA, and antisense.

34. (Currently Amended) The use of ~~any one of claims 31 to 33~~ claim 33, wherein 10 µg to 10 mg of the polynucleotide per dose is ~~injected/subcutaneously~~ injected or subcutaneously introduced in portions to multiple sites around the diseased skin.

35. (Currently Amended) The use of ~~any one of claims 31 to 34~~ claim 31 or 32, wherein the needleless syringe injects the pharmaceutical liquid by using a gas pressure or an elastic force of an elastic member to drive a piston.

36. (Original) The use of claim 35, wherein the gas is helium, nitrogen, or air, and the elastic member is a spring.

37. (Currently Amended) The use of ~~any one of claims 31 to 36~~ claim 31 or 32, wherein the polynucleotide ~~is~~ comprises an HGF gene ~~and/or PGIS gene, a PGIS gene, or both.~~

38. (Currently Amended) The use of ~~any one of claims 31 to 37~~ claim 33, wherein the oligonucleotide is an NF-κB decoy oligonucleotide that comprises the sequence of SEQ ID NO: 1 or 2.

39. (Currently Amended) The use of ~~any one of claims 31 to 38~~ claim 31 or 32, wherein the skin disorder is a wound, cutaneous ulcer, or psoriasis.

40. (Currently Amended) The use of ~~any one of claims 31 to 39~~ claim 39, wherein the wound is a post-surgical wound or a wound caused by an injury or accident.

41. (Currently Amended) The use of ~~any one of claims 31 to 40~~ claim 39, wherein the cutaneous ulcer is an intractable cutaneous ulcer.

42. (Currently Amended) The use of ~~any one of claims 31 to 41~~ claim 41, wherein the intractable cutaneous ulcer is a diabetic ulcer, bedsore (pressure ulcer), or ulcer associated with venous or arterial insufficiency.

43. (Currently Amended) Use of an HGF gene ~~and/or~~ or PGIS gene for preparing an agent for treating, ameliorating, or preventing a wound or cutaneous ulcer, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced around diseased skin using a needleless syringe.

44. (Currently Amended) The use of claim 43 of the HGF gene and PGIS gene for preparing an agent for treating, ameliorating, or preventing a wound or cutaneous ulcer, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced around diseased skin using a needleless syringe.

45. (Currently Amended) Use of an NF- κ B decoy oligonucleotide for preparing an agent for treating, ameliorating, or preventing psoriasis, wherein the agent is ~~injected/subcutaneously~~ injected or subcutaneously introduced around diseased skin using a needleless syringe.